Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H19F2N3O3 |
| Molecular Weight | 387.38 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C(=O)C1=CC2=C(NC(C)=N2)C(O[C@H]3CCOC4=CC(F)=CC(F)=C34)=C1
InChI
InChIKey=CLIQCDHNPDMGSL-HNNXBMFYSA-N
InChI=1S/C20H19F2N3O3/c1-10-23-14-6-11(20(26)25(2)3)7-17(19(14)24-10)28-15-4-5-27-16-9-12(21)8-13(22)18(15)16/h6-9,15H,4-5H2,1-3H3,(H,23,24)/t15-/m0/s1
| Molecular Formula | C20H19F2N3O3 |
| Molecular Weight | 387.38 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Tegoprazan is an oral, selective, reversible inhibitor of gastric H+/K+-ATPase that has a fast onset of action and can control gastric pH for a prolonged period. It was developed for the treatment of acid-related gastrointestinal diseases such as gastroesophageal reflux disease (GERD) and peptic ulcers. Tegoprazan has received a license from the Ministry of Food and Drug Safety in Korea for the treatment of gastroesophageal reflux disease and erosive oesophagitis. In addition, the drug is involved in phase III clinical trial to evaluate the triple therapy (tegoprazan, amoxicillin, and clarithromycin) in H. Pylori positive patients. This trial is on the stage of recruiting the patients.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effects of Tegoprazan, a Novel Potassium-Competitive Acid Blocker, on Rat Models of Gastric Acid-Related Disease. | 2019-06 |
|
| Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. | 2019-04 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:55:38 GMT 2025
by
admin
on
Mon Mar 31 19:55:38 GMT 2025
|
| Record UNII |
W017G7IF4S
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29723
Created by
admin on Mon Mar 31 19:55:38 GMT 2025 , Edited by admin on Mon Mar 31 19:55:38 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
300000020956
Created by
admin on Mon Mar 31 19:55:38 GMT 2025 , Edited by admin on Mon Mar 31 19:55:38 GMT 2025
|
PRIMARY | |||
|
10169
Created by
admin on Mon Mar 31 19:55:38 GMT 2025 , Edited by admin on Mon Mar 31 19:55:38 GMT 2025
|
PRIMARY | |||
|
23582846
Created by
admin on Mon Mar 31 19:55:38 GMT 2025 , Edited by admin on Mon Mar 31 19:55:38 GMT 2025
|
PRIMARY | |||
|
942195-55-3
Created by
admin on Mon Mar 31 19:55:38 GMT 2025 , Edited by admin on Mon Mar 31 19:55:38 GMT 2025
|
PRIMARY | |||
|
C152542
Created by
admin on Mon Mar 31 19:55:38 GMT 2025 , Edited by admin on Mon Mar 31 19:55:38 GMT 2025
|
PRIMARY | |||
|
DB16690
Created by
admin on Mon Mar 31 19:55:38 GMT 2025 , Edited by admin on Mon Mar 31 19:55:38 GMT 2025
|
PRIMARY | |||
|
W017G7IF4S
Created by
admin on Mon Mar 31 19:55:38 GMT 2025 , Edited by admin on Mon Mar 31 19:55:38 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
|
REAGENT->PARENT |
One of the reagent and used in intermediate
(TK-1).
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
IMPURITY -> PARENT |
By product of P-Toluene sulfonyl chloride, which was used in starting material-1 (RM-1879)
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
